Pharminent

NICE recommends AstraZeneca lung treatment

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) is has emerged, meaning the therapy could soon be available for routine use on the NHS. The assessment covers adults whose severe COPD has not responded to other treatments.
read more http://www.pharmafile.com/news/514510/nice-recommends-astrazeneca-lung-treatment

Filed under: COPD

Chiesi backs up COPD triple therapy with real world study

Italian firm takes on mighty GSK
The post Chiesi backs up COPD triple therapy with real world study appeared first on Pharmaphorum. https://pharmaphorum.com/news/chiesi-looks-real-world-study-copd-contender/

Filed under: COPD

GOLD guidelines for the management of COPD – 2017 update

Chronic obstructive lung disease (COPD) is the third leading cause of death in the United States1 and a major cause of mortality and morbidity around the world. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a new “2017 Report”2 with modified recommendations for the diagnosis, management, and prevention of COPD. The report contains […] http://www.pm360online.com/gold-guidelines-for-the-management-of-copd-2017-update/

Filed under: COPD

Circassia signs deal for US rights to two AstraZeneca COPD drugs

UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD). http://drugdiscovery.pharmaceutical-business-review.com/news/circassia-secures-us-rights-for-two-astrazeneca-copd-drugs-for-230m-200317-5766626

Filed under: COPD

Boehringer signs COPD research deal with Weill

Boehringer Ingelheim and Weill Cornell Medicine are working together to identify novel treatment approaches that could halt or even reverse lung tissue damage in coronary obstructive pulmonary disorder (COPD). http://www.pharmatimes.com/news/boehringer_signs_copd_research_deal_with_weill_1186847

Filed under: COPD

Propeller Health, Novartis to Develop Add-On Sensor for Breezhaler

Propeller Health, a Madison, WI-based startup that makes Internet-connected inhalers and sensors designed to help asthma and chronic obstructive pulmonary disease (COPD) patients, says it is teaming up with Novartis to build an add-on sensor for the Swiss pharma giant’s Breezhaler device. The agreement, announced on Wednesday, is focused on patients with COPD who live […] http://www.xconomy.com/wisconsin/2017/02/08/propeller-health-novartis-to-develop-add-on-sensor-for-breezhaler/

Filed under: COPD

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will
improve clinical trial engagement http://www.pmlive.com/pharma_news/gsk_targets_copd_adherence_with_integrated_inhaler_sensors_1183188

Filed under: COPD

Novartis out-licenses three COPD products in the US

EAST HANOVER, N.J., Dec. 21, 2016 /PRNewswire/ — Novartis announced today that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for the US commercial rights to its three treatments for chronic obstructive pulmonary disease (COPD),  Utibron™ Neohaler® (inda… http://www.prnewswire.com/news-releases/novartis-out-licenses-three-copd-products-in-the-us-300382452.html

Filed under: COPD

GSK seeks EU approval for inhaled triple combo COPD therapy

GlaxoSmithKline (GSK) is seeking approval in Europe for once-daily closed triple combination therapy to treat chronic obstructive pulmonary disease (COPD) patients. http://www.pharmaceutical-business-review.com/news/gsk-and-innoviva-seek-eu-approval-for-copd-therapy-candidate-051216-5687325

Filed under: COPD

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application http://www.pmlive.com/pharma_news/gsk_files_first_application_for_triple_copd_therapy_1177783

Filed under: COPD

Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials

A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease. http://clinicaltrials.pharmaceutical-business-review.com/news/theravance-and-mylans-copd-treatment-shows-benefits-in-phase-3-trials-211016-5039060

Filed under: COPD

New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk

RIDGEFIELD, Conn., Oct. 17, 2016 /PRNewswire/ — Boehringer Ingelheim today announced new data analyses from the Phase III TONADO® 1&2 trials that build upon existing evidence about the factors that increase the risk of a COPD exacerbation. These data were presented today at the… http://www.prnewswire.com/news-releases/new-data-analyses-provide-insights-that-may-help-predict-copd-exacerbation-risk-300345675.html

Filed under: COPD

GSK announce positive results from the COPD Salford Lung Study

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar® Ellipta® in patients with chronic obstructive pulmonary disease (COPD), compared with their ‘usual care’ administered in an everyday clinical practice setting. http://www.worldpharmanews.com/gsk/3613-gsk-announce-positive-results-from-the-copd-salford-lung-study

Filed under: COPD

GSK’s triple COPD combination therapy meets two co-primary endpoints in phase III study

GlaxoSmithKline’s (GSK) investigational once-daily closed triple combination therapy was superior to AstraZeneca’s twice-daily Symbicort Turbohaler (budesonide/formoterol 400/12 mcg) in a phase III study in patients with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.pharmaceutical-business-review.com/news/gsks-triple-copd-combination-therapy-meets-two-co-primary-endpoints-in-phase-iii-study-210616-4929021

Filed under: COPD

Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray

RIDGEFIELD, Conn. and NORWALK, Conn., June 8, 2016 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals Inc. and HealthPrize Technologies today announced the launch of RespiPoints™, a free online program that educates, engages, and rewards people who are treating their COPD… http://www.prnewswire.com/news-releases/boehringer-ingelheim-and-healthprize-partner-to-launch-new-support-program-for-people-treating-copd-with-spiriva-respimat-tiotropium-bromide-inhalation-spray-300281491.html

Filed under: COPD

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016 http://www.pmlive.com/pharma_news/gsk_brings_forward_triple_copd_therapy_filing_in_us_1033240

Filed under: COPD

GSK’s Relvar Ellipta hits the mark in COPD trial

A “ground-breaking" UK study has shown that GlaxoSmithKline’s Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). http://www.pharmatimes.com/news/gsks_relvar_ellipta_hits_the_mark_in_copd_trial_1029760

Filed under: COPD

Novartis’ inhaler beats GSK’s Seretide on cutting COPD measure

Novartis’ inhaler beats GSK’s Seretide on cutting COPD measure http://pharmatimes.com/Article/16-05-16/Novartis_inhaler_beats_GSK_s_Seretide_on_cutting_COPD_measure.aspx

Filed under: COPD

US approval for AZ’ new COPD inhaler

US approval for AZ’ new COPD inhaler http://pharmatimes.com/Article/16-04-26/US_approval_for_AZ_new_COPD_inhaler.aspx

Filed under: COPD

3M Launches ‘Intelligent’ COPD Inhaler Designed To Improve Patient Adherence

3M Drug Delivery Systems introduces the 3M™ Intelligent Control Inhaler. This intuitive, fully-integrated device delivers accurate doses to patients while providing on-screen instructions for use, and feedback for the patient and health care provider to use via an app. The 3M Intelligent Control Inhaler provides a number of unique features that offer opportunities to improve outcomes by reducing patient variability and errors, and providing data on use to health care providers and payers. http://www.meddeviceonline.com/doc/3m-launches-intelligent-copd-inhaler-designed-to-improve-patient-adherence-0001

Filed under: COPD

Categories